The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors

BACKGROUND: Inter-individual differences in response to immune checkpoint inhibitors (ICI) remain a major challenge in cancer treatment. The composition of the gut microbiome has been associated with differential ICI outcome, but the underlying molecular mechanisms remain unclear, and therapeutic mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Joachim, Laura, Göttert, Sascha, Sax, Anna, Steiger, Katja, Neuhaus, Klaus, Heinrich, Paul, Fan, Kaiji, Orberg, Erik Thiele, Kleigrewe, Karin, Ruland, Jürgen, Bassermann, Florian, Herr, Wolfgang, Posch, Christian, Heidegger, Simon, Poeck, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597767/
https://www.ncbi.nlm.nih.gov/pubmed/37865045
http://dx.doi.org/10.1016/j.ebiom.2023.104834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10597767/
https://www.ncbi.nlm.nih.gov/pubmed/37865045
http://dx.doi.org/10.1016/j.ebiom.2023.104834

Ejemplares similares